Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Fallen Revenue, Swollen Net Loss in Q3

NEW YORK, Oct. 31 - Transgenomic reported a decrease in third-quarter revenue, increased R&D spending, and a widened net loss.

 

For the three months ended Sept. 30, the company posted $9.1 million in revenue, an 11-percent drop-off compared with $10.3 million in the same quarter one year ago.

 

R&D spending in the quarter increased to $3.2 million from $2.2 million year over year, Transgenomic said.

 

As a result, third-quarter net loss blossomed to $4.7 million, or $.20 per share, from $1.9 million, or $.08 per share one year ago.

 

CEO Collin D'Silva said he has "confidence" that Transgenomics' instruments business "will regain its past momentum" next year. "We are optimistic about our opportunities to advance [the] Wave technology into higher-value markets such as molecular diagnostics and theranostic applications in oncology," he said.

 

Transgenomic said it had around $18.4 million in cash, cash equivalents, and short-term investments as of Sept. 30.

 

Click here for more information.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.